The initial medical treatment with a combination of an alpha-blocker and an antimuscarinic or beta-3 adrenoceptor agonist has been recommended in treating men with LUTS suggestive of benign prostatic hyperplasia (LUTS/BPH) with predominantly storage symptoms [6,7]. The gene discussed is ADRB3; the disease is benign prostatic hyperplasia.